Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Aligos Therapeutics to post earnings of ($2.63) per share and revenue of $0.43 million for the quarter.
Aligos Therapeutics Stock Down 14.0 %
Shares of Aligos Therapeutics stock opened at $14.50 on Tuesday. The company has a market cap of $52.03 million, a PE ratio of -1.09 and a beta of 2.45. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $46.80. The business has a 50 day moving average price of $29.41 and a 200-day moving average price of $20.58.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Read More
- Five stocks we like better than Aligos Therapeutics
- What is the NASDAQ Stock Exchange?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Stock Market Sectors: What Are They and How Many Are There?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
